{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T03:20:55Z","timestamp":1768533655831,"version":"3.49.0"},"reference-count":16,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T00:00:00Z","timestamp":1484265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1005308","type":"journal-article","created":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T13:25:18Z","timestamp":1484313918000},"page":"e1005308","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":93,"title":["A Computational Approach for Identifying Synergistic Drug Combinations"],"prefix":"10.1371","volume":"13","author":[{"given":"Kaitlyn M.","family":"Gayvert","sequence":"first","affiliation":[]},{"given":"Omar","family":"Aly","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4286-446X","authenticated-orcid":true,"given":"James","family":"Platt","sequence":"additional","affiliation":[]},{"given":"Marcus W.","family":"Bosenberg","sequence":"additional","affiliation":[]},{"given":"David F.","family":"Stern","sequence":"additional","affiliation":[]},{"given":"Olivier","family":"Elemento","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2017,1,13]]},"reference":[{"issue":"20","key":"ref1","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"JA Curtin","year":"2005","journal-title":"The New England journal of medicine"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1158\/2159-8290.CD-12-0408","article-title":"Genotype-selective combination therapies for melanoma identified by high-throughput drug screening","volume":"3","author":"MA Held","year":"2013","journal-title":"Cancer discovery"},{"issue":"26","key":"ref3","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"PB Chapman","year":"2011","journal-title":"The New England journal of medicine"},{"issue":"9","key":"ref4","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/nchembio817","article-title":"Systems biology and combination therapy in the quest for clinical efficacy","volume":"2","author":"JB Fitzgerald","year":"2006","journal-title":"Nat Chem Biol"},{"issue":"7458","key":"ref5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/499291a","article-title":"Cancer: calculated treatment","volume":"499","author":"NL Komarova","year":"2013","journal-title":"Nature"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/msb.2011.71","article-title":"Systematic exploration of synergistic drug pairs","volume":"7","author":"M Cokol","year":"2011","journal-title":"Mol Syst Biol"},{"issue":"12","key":"ref7","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/nbt.3052","article-title":"A community computational challenge to predict the activity of pairs of compounds","volume":"32","author":"M Bansal","year":"2014","journal-title":"Nature biotechnology"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"e00149","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"J Foucquier","year":"2015","journal-title":"Pharmacol Res Perspect"},{"issue":"6","key":"ref9","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nrmicro2133","article-title":"Drug interactions and the evolution of antibiotic resistance","volume":"7","author":"PJ Yeh","year":"2009","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"TC Chou","year":"2010","journal-title":"Cancer Res"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"C Robert","year":"2015","journal-title":"The New England journal of medicine"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/A:1010933404324","article-title":"Random forests","volume":"45","author":"L Breiman","year":"2001","journal-title":"Machine Learning"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"e0140310","DOI":"10.1371\/journal.pone.0140310","article-title":"Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR\/PDGFR Combination Treatment","volume":"10","author":"AA Friedman","year":"2015","journal-title":"PloS one"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"e16882","DOI":"10.1371\/journal.pone.0016882","article-title":"Effectiveness of carboplatin and paclitaxel as first- and second-line treatment in 61 patients with metastatic melanoma","volume":"6","author":"A Pflugfelder","year":"2011","journal-title":"PloS one"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"699","DOI":"10.7314\/APJCP.2015.16.2.699","article-title":"Treatment of vemurafenib-resistant SKMEL-28 melanoma cells with paclitaxel","volume":"16","author":"ND Thang","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"issue":"23","key":"ref16","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.2012.43.4233","article-title":"Maximum-tolerated dose, optimum biologic dose, or optimum clinical value: dosing determination of cancer therapies","volume":"30","author":"J Marshall","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pcbi.1005308","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T20:51:25Z","timestamp":1588971085000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1005308"}},"subtitle":[],"editor":[{"given":"Kevin","family":"Chen","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2017,1,13]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1005308","relation":{},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,13]]}}}